Prescribing information



A targeted and precisely delivered B-cell therapy1,2

Sustained B-cell depletion over the dosing period with
KESIMPTA from ASCLEPIOS I and II (pooled analysis)1–3

Reduction of B cells was seen as early as 1 week after treatment initiation3,4

Monthly dosing maintained consistent levels of B-cell depletion with a 20 mg dose1,2


Steady B-cell repletion upon discontinuation of KESIMPTA*1,2,5

Relapsing forms of MS Phase 3 clinical studies indicate a median time to B-cell recovery to LLN or baseline value of 24.6 weeks post-treatment discontinuation†1,2

LLN=lower limit of normal.

*Based on pharmacokinetic B-cell modelling (B cell model: an indirect response model to describe the stimulation of B-cell lysis by free ofatumumab concentrations) of B-cell counts from 1,461 patients with subcutaneous KESIMPTA administration and 25 patients with intravenous KESIMPTA administration across five pooled studies MIRROR, OMS115102, ASCLEPIOS I & II and APLIOS). Simulation is for subcutaneous route with pre-filled syringe and using Phase 3 dosing regimen.

Kesimpta targets B-cell subsets that facilitate inflammation in MS1,2



Click here for KESIMPTA (ofatumumab) prescribing information

Kesimpta targets CD20-inducing lysis of B cells1,2



Click here for KESIMPTA (ofatumumab) prescribing information


  1. KESIMPTA [Summary of Product Characteristics]. Great Britain: Novartis Pharmaceuticals UK Ltd; April 2021.
  2. KESIMPTA [Summary of Product Characteristics]. Novartis Ireland Limited; March 2021.
  3. Hauser SL, Bar-Or A, Cohen J, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials [Poster P7.1-013]. Presented at: AAN; 25 April–1 May 2020; Toronto, Canada [cancelled].
  4. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. New Engl J Med. 2020;383(6):546–557.
  5. Graham G, Yu H, David OJ, et al. Rapid and sustained B-cell depletion with ofatumumab: Population pharmacokinetic B-cell modeling in relapsing multiple sclerosis patients [PO396]. Presented at: 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020; 11–13 September 2020.
Rate this content: 
No votes yet
UK | June 2021 | 132034

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]